Professor Michael S. Hofman
Professor Michael S. Hofman
Consultant Physician, Peter MacCallum Cancer Centre & University of Melbourne
Verified email at petermac.org
Title
Cited by
Cited by
Year
Sensitivity, specificity, and predictors of positive 68Ga–prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and …
M Perera, N Papa, D Christidis, D Wetherell, MS Hofman, DG Murphy, ...
European urology 70 (6), 926-937, 2016
6212016
International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers
A Biggi, A Gallamini, S Chauvie, M Hutchings, L Kostakoglu, M Gregianin, ...
Journal of Nuclear Medicine 54 (5), 683-690, 2013
2512013
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
MS Hofman, J Violet, RJ Hicks, J Ferdinandus, SP Thang, T Akhurst, ...
The Lancet Oncology 19 (6), 825-833, 2018
2452018
The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale
A Gallamini, SF Barrington, A Biggi, S Chauvie, L Kostakoglu, ...
Haematologica 99 (6), 1107-1113, 2014
2062014
Somatostatin Receptor Imaging with 68Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation
MS Hofman, WFE Lau, RJ Hicks
Radiographics 35 (2), 500-516, 2015
2002015
High management impact of Ga‐68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours
MS Hofman, G Kong, OC Neels, P Eu, E Hong, RJ Hicks
Journal of medical imaging and radiation oncology 56 (1), 40-47, 2012
1852012
Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution …
M Perera, N Papa, M Roberts, M Williams, C Udovicich, I Vela, ...
European urology 77 (4), 403-417, 2020
1232020
Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system
JM Beauregard, MS Hofman, JM Pereira, P Eu, RJ Hicks
Cancer Imaging 11 (1), 56, 2011
992011
Is there still a role for SPECT–CT in oncology in the PET–CT era?
RJ Hicks, MS Hofman
Nature reviews Clinical oncology 9 (12), 712, 2012
982012
Prostate-specific membrane antigen ligands for imaging and therapy
M Eiber, WP Fendler, SP Rowe, J Calais, MS Hofman, T Maurer, ...
J Nucl Med 58 (Suppl 2), 67S-76S, 2017
962017
Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls
MS Hofman, RJ Hicks, T Maurer, M Eiber
Radiographics 38 (1), 200-217, 2018
902018
Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial
S Siva, M Bressel, DG Murphy, M Shaw, S Chander, J Violet, KH Tai, ...
European urology 74 (4), 455-462, 2018
862018
Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT
RJ Clifton-Bligh, MS Hofman, E Duncan, IW Sim, D Darnell, A Clarkson, ...
The Journal of Clinical Endocrinology & Metabolism 98 (2), 687-694, 2013
762013
Validating and improving CT ventilation imaging by correlating with ventilation 4D‐PET/CT using 68Ga‐labeled nanoparticles
J Kipritidis, S Siva, MS Hofman, J Callahan, RJ Hicks, PJ Keall
Medical physics 41 (1), 011910, 2014
742014
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy
JM Beauregard, MS Hofman, G Kong, RJ Hicks
European journal of nuclear medicine and molecular imaging 39 (1), 50-56, 2012
722012
68Ga PET/CT ventilation–perfusion imaging for pulmonary embolism: a pilot study with comparison to conventional scintigraphy
MS Hofman, JM Beauregard, TW Barber, OC Neels, P Eu, RJ Hicks
Journal of Nuclear Medicine 52 (10), 1513-1519, 2011
712011
A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to …
MS Hofman, DG Murphy, SG Williams, T Nzenza, A Herschtal, ...
BJU international 122 (5), 783-793, 2018
672018
Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
CY Cheah, MS Hofman, M Dickinson, A Wirth, D Westerman, SJ Harrison, ...
British journal of cancer 109 (2), 312-317, 2013
672013
Favourable outcomes of 177Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours
R Kashyap, MS Hofman, M Michael, G Kong, T Akhurst, P Eu, D Zannino, ...
European journal of nuclear medicine and molecular imaging 42 (2), 176-185, 2015
662015
The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy
ANM Wong, GA McArthur, MS Hofman, RJ Hicks
European journal of nuclear medicine and molecular imaging 44 (1), 67-77, 2017
652017
The system can't perform the operation now. Try again later.
Articles 1–20